As the largest owner and operator of diagnostic imaging centers in the U.S., RadNet (NASDAQ: RDNT) is a one-stop-shop for medical imaging. Providing X-rays, ultrasounds, CT scans, and MRIs, the radiology company valued at $1.8 billion will likely get a boost to its growth as a result of the recent FDA approval of Alzheimer's disease treatment aducanumab , developed by Biogen (NASDAQ: BIIB) and Eisai (OTC: ESALY) .
The arrival of aducanumab, to be marketed as Aduhelm, will spark an immediate surge in the need for advanced imaging, because those who are prescribed the drug will need a number of scans. One in particular is the amyloid PET scan, which detects the buildup of certain plaques in the brain that are believed to play a role in the development of Alzheimer's disease.
Advocating for insurance coverage of amyloid PET scans is a central pillar of Biogen's rollout of Aduhelm. Medicare and Medicaid don't currently cover this particular type of imaging. But at a cost of $4,000 to $5,000 per test, and with an estimated 1 million to 2 million Alzheimer's disease patients in the U.S., there's a potential multibillion-dollar addressable market in this indication alone.
For further details see:
Did This Company Just Win Big Because of Biogen?